Neurocrine Biosciences (NBIX) Enterprise Value (2016 - 2025)
Neurocrine Biosciences (NBIX) has disclosed Enterprise Value for 15 consecutive years, with -$767.4 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Enterprise Value rose 28.69% year-over-year to -$767.4 million, compared with a TTM value of -$1.1 billion through Sep 2025, up 9.22%, and an annual FY2025 reading of -$767.4 million, up 28.69% over the prior year.
- Enterprise Value was -$767.4 million for Q4 2025 at Neurocrine Biosciences, up from -$1.1 billion in the prior quarter.
- Across five years, Enterprise Value topped out at -$765.9 million in Q3 2021 and bottomed at -$1.2 billion in Q3 2024.
- Average Enterprise Value over 4 years is -$993.4 million, with a median of -$984.7 million recorded in 2023.
- The sharpest move saw Enterprise Value plummeted 34.15% in 2024, then rose 28.69% in 2025.
- Year by year, Enterprise Value stood at -$765.9 million in 2021, then plummeted by 35.74% to -$1.0 billion in 2023, then fell by 3.51% to -$1.1 billion in 2024, then grew by 28.69% to -$767.4 million in 2025.
- Business Quant data shows Enterprise Value for NBIX at -$767.4 million in Q4 2025, -$1.1 billion in Q3 2025, and -$975.6 million in Q2 2025.